Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06207799 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Post-transplant MRD-guided Maintenance Therapy
Pre-transplant Purging

Interventions

DRUG: Elranatamab
DRUG: Lenalidomide
DRUG: Plerixafor
DRUG: Melphalan
DRUG: Busulfan
DRUG: G-CSF
PROCEDURE: Stem cell transplant

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]